This is a translation of the original article in Portuguese. Read the original (Português).
The U.S. regulator, the Food and Drug Administration (FDA), has approved giredestranto, a tablet from the Swiss drugmaker Roche to treat advanced or metastatic breast cancer. The information comes from the American newspaper The Wall Street Journal.
The drug was cleared for use in combination with Afinitor, a product of Novartis. Because it is an oral treatment, it is taken as a tablet, not administered by injection or infusion.
For now, the approval covers only advanced or metastatic disease, when the tumor has already spread to other parts of the body. Use at an earlier stage of the disease still awaits a decision from the American agency.
According to the newspaper, Roche executives say giredestranto could become the company’s best-selling product. That assessment signals the drugmaker’s commercial bet on the medication.
What changes for Brazilian patients
The FDA decision applies to the U.S. market and does not, by itself, bring the medication to pharmacies and hospitals in Brazil. To be sold in the country, the drug must be evaluated and approved by Anvisa, Brazil’s health regulator.
After registration, there is another step: incorporation into Brazil’s Unified Health System (SUS) and inclusion in the coverage lists of private health plans. The responsible bodies still need to detail how and when that could happen.
Breast cancer affects thousands of women in Brazil, and oral treatments are often seen as a simpler alternative to therapies that require frequent hospital visits. For that reason, the arrival of a new drug of this kind usually generates expectations among patients and doctors.
For now, what is confirmed is the U.S. approval, for advanced or metastatic disease and in combination with Afinitor. Any extension to earlier-stage cases depends on a new FDA decision.
Reporting from The Wall Street Journal (p. 1 (edição dos Estados Unidos)), The Wall Street Journal (p. 23 (edição da Suíça)).
Deixe um comentário